|
|
 Re: WHO Issues Guidelines for Antiviral Treatment of H1N1 and Other Influenza (Re: ombadda)
|
Recommendationsfor chemoprophylaxis of H1N1
Specific recommendations regarding the use of antivirals for chemoprophylaxis
of pandemic (H1N1) 2009 influenza virus infection are as follows:
When risk for human-to-human transmission of influenza is high or low, and the probability of complications
of infection is high, either because of the influenza strain or because of the baseline risk of the exposed
group, use of oseltamivir or zanamivir may be considered as postexposure chemoprophylaxis for the affected
community or group, for individuals in at-risk groups, or for healthcare workers (weak recommendation, moderate-quality evidence).
Individuals in at-risk groups or healthcare personnel do not need to be offered antiviral chemoprophylaxis if the
likelihood of complications of infection is low. This recommendation should be applied independent of risk for
human-to-human transmission (weak recommendation, low-quality evidence).
For treatment of mild to moderate uncomplicated clinical presentation of infection with multiple cocirculating
influenza A subtypes or viruses with different antiviral susceptibilities, patients in at-risk groups should be
treated with zanamivir or oseltamivir plus M2 inhibitor (noting that amantadine should not be used in
pregnant women). Otherwise-healthy patients with this presentation need not be treated.
When the clinical presentation of infection with multiple cocirculating influenza A subtypes
or viruses with different antiviral susceptibilities is severe or progressive,
all patients should be treated with oseltamivir plus M2 inhibitor, or zanamivir.
For treatment of mild to moderate uncomplicated clinical presentation of infection with sporadic
zoonotic influenza A viruses including H5N1, the at-risk population should be treated with
oseltamivir or zanamivir, and the otherwise-healthy population with oseltamivir.
All patients, regardless of risk status, with severe or progressive presentation of infection
with sporadic zoonotic influenza A viruses including H5N1 should be treated with oseltamivir plus an M2 inhibitor.
|
|
 
|
|
|
|
ombadda
فيس بوك
تويتر
انستقرام
يوتيوب
بنتيريست